Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
DE000A1EWVY8
Tue, 29.03.2022
Formycon AG
Publication of insider information in accordance to Article 17 of Regulation (EU) No. 596/2014Ad Hoc Announcement // March 29, 2022
Formycon and ATHOS KG merge development activities through the acquisition of biosimilar assets in a long-term strategic partnership
Munich - Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) ("Formycon") and ATHOS KG ( [ … ]
Mon, 18.10.2021
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // October 18, 2021
Formycon Concludes Collaboration and License Agreement with SCG Cell Therapy for its COVID-19 Drug FYB207 for the Asia Pacific Region
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and SCG Cell Therap [ … ]
Fri, 01.10.2021
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // October 1, 2021
Formycon and Bioeq announce File Acceptance for FYB201, a biosimilar candidate to Lucentis(R) (ranibizumab) by the U.S. Food and Drug Administration (FDA)
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) [ … ]
Thu, 05.08.2021
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // August 5, 2021
Formycon and Bioeq announce submission of the biologics license application (BLA) for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the U.S. Food and Drug Administration (FDA)
Munich - Formyco [ … ]
Mon, 12.07.2021
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // July 12, 2021
Formycon receives Euro 12.7 million grant for further development of COVID-19 drug FYB207 as part of the Bavarian Therapy Strategy to combat the COVID-19 pandemic
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A [ … ]
Tue, 29.06.2021
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // June 29, 2021
Formycon and Bioeq announce submission of the marketing authorization application for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the European Medicines Agency (EMA)
Munich - Formycon AG (ISI [ … ]
Mon, 28.06.2021
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // June 28, 2021
Formycon announces conclusion of exclusive commercialization agreement between Bioeq AG and Teva Pharmaceutical Industries Ltd. for FYB201 in Europe, Canada, Israel and New Zealand
Munich - Bioeq AG ("Bioeq"), t [ … ]
Thu, 05.11.2020
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad-Hoc Announcement /// November 5, 2020
Formycon informs about the modified BLA-Submission Strategy for its Lucentis(R)* Biosimilar-Candidate FYB201
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its licensing partner Bioeq AG ("Bioeq" [ … ]
Mon, 12.10.2020
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // Oct 12, 2020
Formycon places Cash Capital Increase of 25.75 Million Euros with Strategic Investor
Munich - The Management Board of Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) resolved yesterday, with the approval of the Sup [ … ]